powerful AML-vaccine
AML-VACCiN consortium
Clinical development
younger AML patients
clinical Phase
personalised AML treatment
clinical profile
clinical practice
AML-targeted immune response
MRD
dendritic-cell vaccine therapy
Phase IIb clinical study
innovative DC vaccine - DCP
older patients
acute myeloid leukaemia
dendritic cell
consolidation therapy
medical scientists
project
European medical institutes
public-private consortium
innovative companies
IIa study
forefront of immunotherapy
years of age
risk of relapse
area of high unmet medical need
minimal residual disease
effective treatment monitoring
deadly rare disease
future studies
selective patient enrolment
efficacy
proof of concept
safety
remission
orchestrated action
outcome
IRDiRC objectives
current status
great potential
conditional approval
children
standard induction
stage
orphan medicinal product
data package
level
addition
biomarker program
line
adults
aim
deliverables